Skip to main content
. 2022 Nov 19;13:21501319221138196. doi: 10.1177/21501319221138196

Figure 4.

Figure 4.

Decision impact of KidneyIntelX risk level on new prescriptions for SGLT2 inhibitors. (a) Post-test result at 6 months in the high- (25%) vs low-risk (7%) groups (OR = 4.56; 95% CI: 3.00-6.91) and (b) the physician type most likely to order SGLT2 inhibitors.